Home Monitoring and Evaluation After Admission for COVID-19 in the Netherlands

COVID-19 Clinical Trial

— HOMECOMIN'  

Official title:

Home Monitoring and Evaluation After Admission for COVID-19 in the Netherlands

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04488562
• Other study ID #: MEC-2020-0318
• Status: Completed
• Start date: March 19, 2020
• Est. completion date: February 26, 2022

Study information

• Verified date: February 2023
• Source: Erasmus Medical Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

To date, little is known about the short and long-term complications of COVID-19. In order to obtain more insights in disease course and recovery of COVID-19 and to improve care after hospital admission, patients with COVID-19 will be monitored at home using an online home monitoring program for a period of 1 year.

Description:

Patients with COVID-19 have a variable disease course and recovery. After the SARS coronavirus outbreak in 2003, many patients developed pulmonary fibrosis. Emerging data from the COVID-19 outbreak suggests that a substantial number of patient will likely develop pulmonary fibrosis. However, much is still unknown (e.g. the percentage of patients who develop pulmonary fibrosis, progression of fibrosis). Since we have little knowledge on the disease course and long-term complications of COVID-19, it is very important to properly monitor patients after hospital admission. An online home monitoring program could be an efficient way to monitor disease course of COVID-19 and provide insights in the long-term effects of COVID-19.

In this prospective, observational multi center study we aim to include 150 patients that were admitted in the hospital with abnormalities on chest X-ray/HRCT due to COVID-19. Based on their clinical status, patients will be either included at time of discharge from the hospital or at time of their regular outpatient clinic visit, 6 weeks after discharge from the hospital. Patients will be monitored for a period of 1 year after admission, after signing informed consent. Home monitoring, consisting of real-time lung function measures and PROMs, has been developed and validated for patients with pulmonary fibrosis; home monitoring was feasible, FVC measurements were reliable and patient satisfaction was high.

Patients are asked to fill in a diary once weekly (consisting of Visual Analogue Scales on cough, dyspnea, fatigue, general well-being, and temperature and oxygen measurements) and measure their lung function (FVC) at home every week with a home spirometer (Spirobank Smart, MIR, Italy) (duration + -2 min). The spirometer is connected via Bluetooth with the secured app and results can be sent directly to the study team. Patients are instructed to contact the hospital using a secured eConsult if they have worsening complaints and/or have a decrease in saturation or lung function.

Patients are asked to fill complete short validated questionnaires (ABC tool, EQ5D-5L, Fatigue Assessment Scale and Global rating of change, duration + - 10 minutes) in the app, at time of discharge, 6 weeks, 3 months, 6 months, 9 months and 12 months after discharge.

Demographic data, clinical characteristics, lung function results, radiology data and data about medication will be collected from the electronic patient file during regular outpatient clinic visits.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 133
• Est. completion date: February 26, 2022
• Est. primary completion date: August 26, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients admitted to the hospital with proven COVID-19 infection

• Abnormalities on Chest X-ray/HRCT due to COVID-19 infection

Exclusion Criteria:

• Not able to speak, read or write in the native language of the country where the patient is included

• Not able to comply to the study protocol, according to the judgement of the investigator and/or patient

• No access to internet

Related Conditions & MeSH terms

• COVID-19
• Pulmonary Fibrosis

Locations

Country	Name	City	State
Netherlands	Amsterdam University Center - location VUmc	Amsterdam
Netherlands	Leiden University Medical Center	Leiden
Netherlands	Erasmus MC	Rotterdam

Sponsors (4)

Lead Sponsor	Collaborator
Erasmus Medical Center	Amsterdam UMC, location VUmc, Dutch Society of Physicians for Pulmonology and Tuberculosis, Leiden University Medical Center

Country where clinical trial is conducted

Netherlands, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	VAS	Visual Analogue Scale: scores on fatigue, dyspnea, cough and general wellbeing on a scale ranging from 0-10. Higher score indicates more complaint.	3 months
Primary	VAS	Visual Analogue Scale: scores on fatigue, dyspnea, cough and general wellbeing on a scale ranging from 0-10. Higher score indicates more complaint.	6 months
Primary	VAS	Visual Analogue Scale: scores on fatigue, dyspnea, cough and general wellbeing on a scale ranging from 0-10. Higher score indicates more complaint.	12 months
Primary	Temperature	Body temperature measured with an thermometer	3 months
Primary	Oxygen measurements	Oxygen saturation measured with an pulse oximeter	3 months
Primary	Oxygen measurements	Oxygen saturation measured with an pulse oximeter	6 months
Primary	Oxygen measurements	Oxygen saturation measured with an pulse oximeter	12 months
Primary	Forced Vital Capacity (FVC) home spirometry in %	FVC change measured with home spirometry at 3 months (in %)	3 months
Primary	Forced Vital Capacity (FVC) home spirometry in L	FVC change measured with home spirometry at 3 months (in L)	3 months
Primary	Forced Vital Capacity (FVC) home spirometry in %	FVC change measured with home spirometry at 6 months (in %)	6 months
Primary	Forced Vital Capacity (FVC) home spirometry in L	FVC change measured with home spirometry at 6 months (in L)	6 months
Primary	Forced Vital Capacity (FVC) home spirometry in L	FVC change measured with home spirometry at 12 months (in L)	12 months
Primary	Forced Vital Capacity (FVC) home spirometry in %	FVC change measured with home spirometry at 12 months (in %)	12 months
Primary	Forced Vital Capacity (FVC) hospital spirometry in %	FVC change measured with hospital spirometry and saturation at 3 months (in %)	3 months
Primary	Forced Vital Capacity (FVC) hospital spirometry in L	FVC change measured with hospital spirometry and saturation at 3 months (in L)	3 months
Primary	Forced Vital Capacity (FVC) hospital spirometry in %	FVC change measured with hospital spirometry and saturation at 6 months (in %)	6 months
Primary	Forced Vital Capacity (FVC) hospital spirometry in L	FVC change measured with hospital spirometry and saturation at 6 months (in L)	6 months
Primary	Forced Vital Capacity (FVC) hospital spirometry in %	FVC change measured with hospital spirometry and saturation at 12 months (in %)	12 months
Primary	Forced Vital Capacity (FVC) hospital spirometry in L	FVC change measured with hospital spirometry and saturation at 12 months (in L)	12 months
Primary	Adherence to weekly home spirometry	The percentage of patients completed weekly home spirometry	1 year after inclusion
Primary	EQ5D	The EuroQol five dimensions 5-level questionnaire: 6-item questionnaire on five dimensions: The EuroQol five dimensions 5-level questionnaire is a standardized instrument to measures health outcomes in two components: health description and valuation. It comprises five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Higher score indicates a poorer health status	Baseline
Primary	EQ5D	The EuroQol five dimensions 5-level questionnaire: 6-item questionnaire on five dimensions: The EuroQol five dimensions 5-level questionnaire is a standardized instrument to measures health outcomes in two components: health description and valuation. It comprises five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Higher score indicates a poorer health status	6 weeks
Primary	EQ5D	The EuroQol five dimensions 5-level questionnaire: 6-item questionnaire on five dimensions: The EuroQol five dimensions 5-level questionnaire is a standardized instrument to measures health outcomes in two components: health description and valuation. It comprises five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Higher score indicates a poorer health status	3 months
Primary	EQ5D	The EuroQol five dimensions 5-level questionnaire: 6-item questionnaire on five dimensions: The EuroQol five dimensions 5-level questionnaire is a standardized instrument to measures health outcomes in two components: health description and valuation. It comprises five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Higher score indicates a poorer health status	6 months
Primary	EQ5D	The EuroQol five dimensions 5-level questionnaire: 6-item questionnaire on five dimensions: The EuroQol five dimensions 5-level questionnaire is a standardized instrument to measures health outcomes in two components: health description and valuation. It comprises five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Higher score indicates a poorer health status	9 months
Primary	EQ5D	The EuroQol five dimensions 5-level questionnaire: 6-item questionnaire on five dimensions: The EuroQol five dimensions 5-level questionnaire is a standardized instrument to measures health outcomes in two components: health description and valuation. It comprises five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Higher score indicates a poorer health status	12 months
Primary	FAS	Fatigue Assessment Scale: 10-item questionnaire about fatigue FAS. The fatigue assessment scale (FAS) is a 10-item self-administered questionnaire about fatigue in patients with sarcoidosis. The score ranges from 5-50 points, with a score of = 22 points as cut-off for fatigue. The minimal important difference (MID) is 4 points or a 10% lower score. It will take about 1-2 minutes to complete.	Baseline
Primary	FAS	Fatigue Assessment Scale: 10-item questionnaire about fatigue FAS. The fatigue assessment scale (FAS) is a 10-item self-administered questionnaire about fatigue in patients with sarcoidosis. The score ranges from 5-50 points, with a score of = 22 points as cut-off for fatigue. The minimal important difference (MID) is 4 points or a 10% lower score. It will take about 1-2 minutes to complete.	6 weeks
Primary	FAS	Fatigue Assessment Scale: 10-item questionnaire about fatigue FAS. The fatigue assessment scale (FAS) is a 10-item self-administered questionnaire about fatigue in patients with sarcoidosis. The score ranges from 5-50 points, with a score of = 22 points as cut-off for fatigue. The minimal important difference (MID) is 4 points or a 10% lower score. It will take about 1-2 minutes to complete.	3 months weeks
Primary	FAS	Fatigue Assessment Scale: 10-item questionnaire about fatigue FAS. The fatigue assessment scale (FAS) is a 10-item self-administered questionnaire about fatigue in patients with sarcoidosis. The score ranges from 5-50 points, with a score of = 22 points as cut-off for fatigue. The minimal important difference (MID) is 4 points or a 10% lower score. It will take about 1-2 minutes to complete.	6 months weeks
Primary	FAS	Fatigue Assessment Scale: 10-item questionnaire about fatigue FAS. The fatigue assessment scale (FAS) is a 10-item self-administered questionnaire about fatigue in patients with sarcoidosis. The score ranges from 5-50 points, with a score of = 22 points as cut-off for fatigue. The minimal important difference (MID) is 4 points or a 10% lower score. It will take about 1-2 minutes to complete.	9 months weeks
Primary	FAS	Fatigue Assessment Scale: 10-item questionnaire about fatigue FAS. The fatigue assessment scale (FAS) is a 10-item self-administered questionnaire about fatigue in patients with sarcoidosis. The score ranges from 5-50 points, with a score of = 22 points as cut-off for fatigue. The minimal important difference (MID) is 4 points or a 10% lower score. It will take about 1-2 minutes to complete.	12 months weeks
Primary	GRoC	Global Rating of Change Scales: Global rating of change (GRC) scales provide a method of obtaining information about improving or deteriorated of health condition of patients over time. Patients are asked to make global ratings on changes in regards to their well-being on a 15-point self-report scale (from -7 to 7 ). It will take about 1 minute to complete. Higher score indicates a better health condition.	Baseline
Primary	GRoC	Global Rating of Change Scales: Global rating of change (GRC) scales provide a method of obtaining information about improving or deteriorated of health condition of patients over time. Patients are asked to make global ratings on changes in regards to their well-being on a 15-point self-report scale (from -7 to 7 ). It will take about 1 minute to complete. Higher score indicates a better health condition.	6 weeks
Primary	GRoC	Global Rating of Change Scales: Global rating of change (GRC) scales provide a method of obtaining information about improving or deteriorated of health condition of patients over time. Patients are asked to make global ratings on changes in regards to their well-being on a 15-point self-report scale (from -7 to 7 ). It will take about 1 minute to complete. Higher score indicates a better health condition.	3 months
Primary	GRoC	Global Rating of Change Scales: Global rating of change (GRC) scales provide a method of obtaining information about improving or deteriorated of health condition of patients over time. Patients are asked to make global ratings on changes in regards to their well-being on a 15-point self-report scale (from -7 to 7 ). It will take about 1 minute to complete. Higher score indicates a better health condition.	6 months
Primary	GRoC	Global Rating of Change Scales: Global rating of change (GRC) scales provide a method of obtaining information about improving or deteriorated of health condition of patients over time. Patients are asked to make global ratings on changes in regards to their well-being on a 15-point self-report scale (from -7 to 7 ). It will take about 1 minute to complete. Higher score indicates a better health condition.	9 months
Primary	GRoC	Global Rating of Change Scales: Global rating of change (GRC) scales provide a method of obtaining information about improving or deteriorated of health condition of patients over time. Patients are asked to make global ratings on changes in regards to their well-being on a 15-point self-report scale (from -7 to 7 ). It will take about 1 minute to complete. Higher score indicates a better health condition.	12 months
Primary	ABC tool	Questionnaire consisting of five domains: symptoms, functional state, mental state, emotions and fatigue, smoking status, exacerbations, dyspnoea, body mass index, lung function and self-reported physical activity. Outcomes are visualized using coloured balloons. green balloons indicate a satisfactory score, red balloons a low score and orange balloons an intermediate score. Grey balloons represent the balloons of previous visits.	Baseline
Primary	ABC tool	Questionnaire consisting of five domains: symptoms, functional state, mental state, emotions and fatigue, smoking status, exacerbations, dyspnoea, body mass index, lung function and self-reported physical activity. Outcomes are visualized using coloured balloons. green balloons indicate a satisfactory score, red balloons a low score and orange balloons an intermediate score. Grey balloons represent the balloons of previous visits.	6 weeks
Primary	ABC tool	Questionnaire consisting of five domains: symptoms, functional state, mental state, emotions and fatigue, smoking status, exacerbations, dyspnoea, body mass index, lung function and self-reported physical activity. Outcomes are visualized using coloured balloons. green balloons indicate a satisfactory score, red balloons a low score and orange balloons an intermediate score. Grey balloons represent the balloons of previous visits.	3 months
Primary	ABC tool	Questionnaire consisting of five domains: symptoms, functional state, mental state, emotions and fatigue, smoking status, exacerbations, dyspnoea, body mass index, lung function and self-reported physical activity. Outcomes are visualized using coloured balloons. green balloons indicate a satisfactory score, red balloons a low score and orange balloons an intermediate score. Grey balloons represent the balloons of previous visits.	6 months
Primary	ABC tool	Questionnaire consisting of five domains: symptoms, functional state, mental state, emotions and fatigue, smoking status, exacerbations, dyspnoea, body mass index, lung function and self-reported physical activity. Outcomes are visualized using coloured balloons. green balloons indicate a satisfactory score, red balloons a low score and orange balloons an intermediate score. Grey balloons represent the balloons of previous visits.	9 months
Primary	ABC tool	Questionnaire consisting of five domains: symptoms, functional state, mental state, emotions and fatigue, smoking status, exacerbations, dyspnoea, body mass index, lung function and self-reported physical activity. Outcomes are visualized using coloured balloons. green balloons indicate a satisfactory score, red balloons a low score and orange balloons an intermediate score. Grey balloons represent the balloons of previous visits.	12 months
Secondary	Correlation between FVC, HRCT patterns, symptoms and quality of life	Correlation between FVC, HRCT patterns, symptoms and quality of life	3 months
Secondary	Correlation between FVC, HRCT patterns, symptoms and quality of life	Correlation between FVC, HRCT patterns, symptoms and quality of life	6 months
Secondary	Correlation between FVC, HRCT patterns, symptoms and quality of life	Correlation between FVC, HRCT patterns, symptoms and quality of life	12 months
Secondary	Predictors for the course of recovery of COVID-19 infection after hospital admission	Predictors for the course of recovery of COVID-19 infection after hospital admission	12 months
Secondary	Satisfaction of patients and caregivers with the use of a home monitoring system	Healthcare provider and patient satisfaction and experience with the online application. Patients and healthcare providers are asked about their experiences and opinions on homemonitoring.	12 months